Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma

Journal of Thoracic Oncology

Volumn 6, Issue 12, 2011, Pages 2130-2134

  Agatsuma, Toshihiko ^a   Koizumi, Tomonobu ^b   Kanda, Shintaro ^a   Ito, Michiko ^a   Urushihata, Kazuhisa ^a   Yamamoto, Hiroshi ^a   Hanaoka, Masayuki ^a   Kubo, Keishi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Chemotherapy; Platinum; Thymic carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; VINCRISTINE;

ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; THYMUS CANCER; TREATMENT RESPONSE; VOMITING;

EID: 81755179378     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31822e71c0     Document Type: Article

References (31)

1. Wick MR, Scheithauer BW, Weiland LH, et al. Primary thymic carcinomas. Am J Surg Pathol 1982;6:613-630. (Pubitemid 13234758)
2. Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer 1991;67:1025-1032.
3. Hsu CP, Chen CY, Chen CL, et al. Thymic carcinoma. Ten years' experience in twenty patients. J Thorac Cardiovasc Surg 1994;107:615-620.
4. Blumberg D, Burt ME, Bains MS, et al. Thymic carcinoma: current staging does not predict prognosis. J Thorac Cardiovasc Surg 1998;115: 303-308.
5. Ogawa K, Toita T, Uno T, et al. Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. Cancer 2002;94:3115-3119. (Pubitemid 34670493)
6. Takeda S, Sawabata N, Inoue M, et al. Thymic carcinoma. Clinical institutional experience with 15 patients. Eur J Cardiothorac Surg 2004;26:401-406. (Pubitemid 39024667)
7. Yano M, Sasaki H, Yokoyama T, et al. Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol 2008;3:265-269. (Pubitemid 351654326)
8. Weide LG, Ulbright TM, Loehrer PJ Sr, et al. Thymic carcinoma. A distinct clinical entity responsive to chemotherapy. Cancer 1993;71: 1219-1223. (Pubitemid 23054909)
9. Nakamura Y, Kunitoh H, Kubota K, et al. Platinum-based chemotherapy with or without thoracic radiation therapy in patients with unresectable thymic carcinoma. Jpn J Clin Oncol 2000;30:385-388.
10. Kitami A, Suzuki T, Kamio Y, et al. Chemotherapy of thymic carcinoma: analysis of seven cases and review of the literature. Jpn J Clin Oncol 2001;31:601-604. (Pubitemid 34116474)
11. Koizumi T, Takabayashi Y, Yamagishi S, et al. Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol 2002;25:266-268. (Pubitemid 34602548)
12. Yoh K, Goto K, Ishii G, et al. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer 2003;98:926-931. (Pubitemid 37022091)
13. Maruyama R, Suemitsu R, Okamoto T, et al. Persistent and aggressive treatment for thymic carcinoma. Results of a single-institute experience with 25 patients. Oncology 2006;70:325-329. (Pubitemid 46066127)
14. Igawa S, Murakami H, Takahashi T, et al. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer 2010;67:194-197.
15. Oshita F, Kasai T, Kurata T, et al. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colonystimulating factor for advanced thymoma or thymic cancer: preliminary results. Jpn J Clin Oncol 1995;25:208-212.
16. Loehrer PJ Sr, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 2001;91: 2010-2015. (Pubitemid 32476364)
17. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer 1991;68:30-33.
18. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC press, 2004.
19. Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48: 2485-2492. (Pubitemid 12228012)
20. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment, Vol. 48. Geneva: WHO offset publication, 1979.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
23. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer. Cancer 1981;47:207-214.
24. National Cancer Institute: Common Toxicity Criteria (CTC) Version 2.0 [National Cancer Institute Web site], 1999. Available at: http://ctep.cancer. gov/protocolDevelopment/electronic-applications/ctc.htm.Accessed March 1, 2011.
25. Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 [National Cancer Institute Web site], 2003. Available at:http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ctc.htm.Accessed March 1, 2011.
26. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5: 649-655. (Pubitemid 13149996)
27. Strobel P, Hohenberger P, Marx A. Thymoma: molecular pathology and targeted therapy. J Thorac Oncol 2010;5:S286-S290.
28. Rajan A, Giaccone G. Targeted therapy for advanced thymic tumors. J Thorac Oncol 2010;5:S361-S364.
29. Bisagni G, Rossi G, Cavazza A, et al. Long lasting response to the multikinase inhibitor bay 43-9006 (sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 2009;4:773-775.
30. Li XF, Chen Q, Huang WX, et al. Response to sorafenib in cisplatinresistant thymic carcinoma: a case report. Med Oncol 2009;26:157-160.
31. Strobel P, Bargou R, Wolff A, et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 2010;103:196-200.